Voriconazole, Serum or Plasma
Also known as: UK-109,496, Vfend®
Use
Treatment of invasive aspergillosis; treatment of esophageal candidiasis; treatment of candidemia; treatment of candida deep tissue infections; treatment of serious fungal infections caused by Scedosporium apiospermum and fusarium spp in patients intolerant or refractory to other therapy.
Special Instructions
It is crucial to follow specific specimen collection instructions to ensure accurate results. For instance, separated serum or plasma should be transferred to a plastic transport tube, avoiding gel-barrier tubes due to the drug's absorption by the gel, which could significantly impact the results.
Limitations
This test was developed, and its performance characteristics were determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA), as the FDA determined that such clearance is not necessary. Results must be carefully interpreted in the context of the clinical conditions and other diagnostic data.
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 38370-3
- 38370-3
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube
Collection Instructions
Transfer separated serum or plasma to a plastic transport tube. Do not use a gel barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel.
Storage Instructions
Refrigerate. Stable for 14 days at room temperature, refrigerated, or frozen.
Causes for Rejection
Gel-barrier tube
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |